Preparation And Storage
The antibody reagent is stable until the expiration date shown on the label when stored at 2° to 8°C. Do not use after the expiration date. Do not freeze the reagent or expose it to direct light during storage or incubation with cells. Keep the outside of the reagent vial dry.
Do not use the reagent if you observe any change in appearance. Precipitation or discoloration indicates instability or deterioration.
CD79a is intended for in vitro diagnostic use in the identification of cells expressing CD79a antigen, using a BD FACS™ brand flow cytometer. The flow cytometer must be equipped to detect light scatter and the appropriate fluorescence, and be equipped with appropriate analysis software (such as BD CellQuest™ or BD LYSYS™ II software) for data acquisition and analysis. Refer to your instrument user’s guide for instructions.
Development References (13)
-
Centers for Disease Control. Update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in healthcare settings. MMWR. 1988; 37:377-388. (Biology).
-
Clinical Applications of Flow Cytometry: Quality Assurance and Immunophenotyping of Lymphocytes: Approved Guideline. H42-A2. 2007. (Biology).
-
Colomo L, Lopez-Guillermo A, Perales M, et al. Clinical impact of the differentiation pro le assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood. 2003; 101:78-84. (Biology).
-
Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies. Rothe G, Schmitz G. Leukemia. 1996; 10:877-895. (Biology).
-
Engel P, Wagner N, Tedder TF. Schlossman SF, Boumsell L, Gilks W, et al, ed. Leucocyte Typing V: White Cell Differentiation Antigens. New York, NY: Oxford University Press; 1995:667-679.
-
Frater JL, Yaseen NR, Peterson LC, Tallman MS, L GsC. Biphenotypic acute leukemia with coexpression of CD79a and markers of meyloid lineage. Arch Pathol Lab Med. 2003; 127:356-359. (Biology).
-
Jackson AL, Warner NL. Rose NR, Friedman H, Fahey JL, ed. Manual of Clincial Laboratory Immunology, Third Edition. Washington DC: American Society for Microbiology; 1986:226-235.
-
Karube K, Ohshima K, Txuchiya R, et al. Non-B, non-T neoplasms with lymphoblast morphology: further clari cation and classification. Am J Surg Pathol. 2003; 27:1366-1374. (Biology).
-
Knowles DM. Knowles DM, Thompson DD, ed. Neoplastic Hematopathology. Philadelphia, PA: Williams & Wilkins; 2001.
-
Mason DY, Cordell JL, Tse AG, et al. The IgM-associated protein mb-1 as a marker of normal and neoplastic B cells. J Immunol. 1991; 147(11):2474-2482. (Biology). View Reference
-
NCCLS document. 2001. (Biology).
-
Sakaguchi N, Kashiwamura S, Kimoto M, Thalmann P, Melchers F. B lymphocyte lineage-restricted expression of mb-1, a gene with CD3-like structural properties. EMBO J. 1988; 7(11):3457-3464. (Biology). View Reference
-
Stelzer GT, Marti G, Hurley A, McCoy PJ, Lovett EJ, Schwartz A. US-Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: standardization and validation of laboratory procedures. Cytometry. 1997; 30:214-230. (Biology).
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For In Vitro Diagnostic Use.
23-22942-00
Documents are subject to revision without notice. Please verify you have the correct revision of the document, and always refer back to BD's eIFU website for the latest and most up to date information.